ÂÜÀòÂÒÂ×

Jeno Gyuris is a seasoned professional in the biotechnology and pharmaceutical sectors, currently serving as a Partner at Cure Ventures since February 2023. Prior to this, Jeno held key leadership roles including Chief Scientific Officer and Co-founder at Sporos Bioventures from June 2019 to January 2023, and Chief Scientific Officer at Tvardi Therapeutics, where the focus was on developing small molecule inhibitors of STAT3 for cancer and other conditions from February 2018 to January 2023. Additional experience includes serving as Chief Scientific Officer at Trieza Therapeutics, which specializes in immunotherapy, and at Quiet Therapeutics, along with a prolonged tenure as Chief Scientific Officer at AVEO Oncology. Jeno's career began at GPC Biotech Inc./Mitotix Inc. in a Vice President role. Jeno completed a postdoctoral fellowship at Harvard Medical School - Massachusetts General Hospital and received education from the University of Szeged.